VC: Ascendis, Cempra, and Arcion raise funds

Denmark's Ascendis Pharma has raised €17.6 million ($25.84 million) in its first round of financing. The round was led by Sofinnova Partners. Ascendis plans to use the money to broaden the company's pipeline and to position itself in the space of lifecycle management of marketed drugs.

- check out the release for more details

ALSO: Cempra Pharmaceuticals, which is developing anti-infective drugs--has garnered $10 million in Series B funding. Backers include Aisling Capital, Intersouth Partners, Optimer Pharmaceuticals Inc. and banker I. Wistar Morris III. Report

PLUS: Arcion Therapeutics has raised $8.85 million in Series A funding. The company is focused on pain management treatments. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.